Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inducer of cancer cell death that holds promise in cancer therapy. Cancer cells are more susceptible than normal cells to the cell-death-inducing effects of TRAIL. However, a variety of cancer cells are resistant to TRAIL through complex mechanisms. Here, we investigate the effects of inhibition of eukaryotic initiation factor 2 subunit a (eIF2a) dephosphorylation on TRAIL-induced apoptosis in hepatoma cells. Treatment of hepatoma cells with salubrinal, an inhibitor of eIF2a dephosphorylation, enhances TRAIL-induced eIF2a phosphorylation, CCAAT/ enhancer-binding protein homologous protein (CHOP) expression and caspase activation. Salubrinal enhances TRAIL-induced apoptosis, which could be abrogated by caspase inhibitor. Overexpression of phosphomimetic eIF2a (S51D) enhances TRAILinduced CHOP expression, caspase 7 and PARP cleavage and apoptosis. By contrast, overexpression of phosphodeficient eIF2a (S51A) abrogates the stimulation of TRAIL-induced apoptosis by salubrinal. Moreover, knockdown of growth arrest and DNA damage-inducible protein 34 (GADD34), which recruits protein phosphatase 1 to dephosphorylate eIF2a, enhances TRAILinduced eIF2a phosphorylation, CHOP expression, caspase activation and apoptosis. Furthermore, the sensitization of hepatoma cells to TRAIL by salubrinal is dependent on CHOP. Knockdown of CHOP abrogates the stimulation of TRAIL-induced caspase activation and apoptosis by salubrinal. Combination of salubrinal and TRAIL leads to increased expression of Bim, a CHOP-regulated proapoptotic protein. Bim knockdown blunts the stimulatory effect of salubrinal on TRAIL-induced apoptosis. Collectively, these findings suggest that inhibition of eIF2a dephosphorylation may lead to synthetic lethality in TRAIL-treated hepatoma cells.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inducer of cancer cell death that holds promise in cancer therapy. Cancer cells are more susceptible than normal cells to the cell-death-inducing effects of TRAIL. However, a variety of cancer cells are resistant to TRAIL through complex mechanisms. Here, we investigate the effects of inhibition of eukaryotic initiation factor 2 subunit a (eIF2a) dephosphorylation on TRAIL-induced apoptosis in hepatoma cells. Treatment of hepatoma cells with salubrinal, an inhibitor of eIF2a dephosphorylation, enhances TRAIL-induced eIF2a phosphorylation, CCAAT/ enhancer-binding protein homologous protein (CHOP) expression and caspase activation. Salubrinal enhances TRAIL-induced apoptosis, which could be abrogated by caspase inhibitor. Overexpression of phosphomimetic eIF2a (S51D) enhances TRAILinduced CHOP expression, caspase 7 and PARP cleavage and apoptosis. By contrast, overexpression of phosphodeficient eIF2a (S51A) abrogates the stimulation of TRAIL-induced apoptosis by salubrinal. Moreover, knockdown of growth arrest and DNA damage-inducible protein 34 (GADD34), which recruits protein phosphatase 1 to dephosphorylate eIF2a, enhances TRAILinduced eIF2a phosphorylation, CHOP expression, caspase activation and apoptosis. Furthermore, the sensitization of hepatoma cells to TRAIL by salubrinal is dependent on CHOP. Knockdown of CHOP abrogates the stimulation of TRAIL-induced caspase activation and apoptosis by salubrinal. Combination of salubrinal and TRAIL leads to increased expression of Bim, a CHOP-regulated proapoptotic protein. Bim knockdown blunts the stimulatory effect of salubrinal on TRAIL-induced apoptosis. Collectively, these findings suggest that inhibition of eIF2a dephosphorylation may lead to synthetic lethality in TRAIL-treated hepatoma cells. Cell Death and Disease (2014) 5, e1060; doi:10.1038/cddis.2014.24; published online 13 February 2014 Subject Category: Cancer TNF-related apoptosis-inducing ligand (TRAIL) is a member of TNF superfamily that has diverse roles in physiological or pathological conditions. 1 A major function of TRAIL is induction of apoptosis. The effects of TRAIL are mediated by cell membrane receptor, including death receptors TRAILR1 (also known as DR4) and TRAILR2 (also known as DR5). Binding of TRAIL to TRAILR1 or TRAILR2 leads to receptor oligomerization and recruitment of the FAS-associated protein with death domain (FADD) to death domain motifs in the carboxyl terminus of the receptor thereby recruiting caspase-8 or caspase-10 to form a multiprotein death-inducing signaling complex. 2 By contrast, the decoy receptors TRAILR3 and TRAILR4 may inhibit TRAIL-induced apoptosis. 3 TRAIL is a promising anticancer agent, because it can induce the apoptosis of tumor cells. [4] [5] [6] Preclinical studies in animal models demonstrate that recombinant TRAIL suppressed some types of human tumor xenografts without apparent systemic toxicity. 4, 5 Although TRAIL is an attractive agent that kills cancer cells other than normal cells, 7 the sensitivity of cancer cells to TRAIL-induced apoptosis may vary among different types of cancer, subpopulations of a given tumor or individual cancer patients. The mechanisms underlying TRAIL resistance are complex. Resistance to TRAIL can occur as a result of disturbance in the signaling pathways triggered by TRAIL, such as dysfunction of the death receptor DR4 and DR5, 8 defects in the FADD and caspase-8 and activation of PI3K/Akt pathway. [9] [10] [11] Akt may inhibit Bid expression thereby leading to resistance to TRAIL-induced apoptosis in ovarian cancer cells. 12 In addition, cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptor in metastatic colon adenocarcinoma cells. 13 Galectin-3 also sensitizes Bt-549 human breast cancer cells to TRAIL by upregulating PTEN and inactivating Akt.
14 On the other hand, overexpression of galectin-3 in human bladder carcinoma cells activates Akt and confers resistance to TRAIL. 15 Eukaryotic initiation factor 2 subunit a (eIF2a) has a key role in the process of mRNA translation. 16 Phosphorylation of eIF2a reduces its activity, thereby impairing general protein synthesis, whereas increasing the synthesis of certain transcription factors and their targets. Phosphorylation of eIF2a at serine 51 is an important adaptive response to 17, 18 Previous studies demonstrate that TNF or TRAILinduced eIF2a phosphorylation is dependent on the doublestranded RNA-regulated protein kinase (PKR). 18 As an important part of integrative stress response, phosphorylation of eIF2a may act as a double-edge sword in cell fate decisions. Upon ER stress, phosphorylation and inactivation of eIF2a is a transient process. Initially, phosphorylation of eIF2a may be cytoprotective as a result of reduced burden for the ER or other cellular machinery. Phosphorylation of eIF2a leads to increased synthesis of activating transcription factor 4 (ATF4) thereby increasing the expression of growth arrest and DNA damage-inducible protein 34 (GADD34), which recruits protein phosphatase 1 to eIF2a and dephosphorylates eIF2a. 19 This in turn results in the recovery of protein synthesis and restoration of homeostasis. Prolonged or unresolved ER stress, however, can induce cell death, which may involve eIF2a phosphorylation and increased ATF4 and CCAAT/enhancer-binding protein homologous protein (CHOP) expression. Thus, sustained phosphorylation of eIF2a may induce cell death, depending on the cell types or context. Salubrinal, a selective inhibitor of eIF2a dephosphorylation, reportedly inhibits ER stress-induced apoptosis in neural cells. 20 However, phosphorylation of eIF2a or treatment with salubrinal enhances proteasome inhibitiorinduced apoptosis in leukemia cells and multiple myeloma cells. [21] [22] [23] In addition, selective inhibition of eIF2a dephosphorylation causes pancreatic beta-cell dysfunction and apoptosis. 24 Hepatoma cells are quite resistant to TRAIL, and TRAIL alone poorly induce apoptotic cell death. 25 Given that TRAIL induces eIF2a phosphorylation, we wish to determine the effects of selective inhibition of eIF2a dephosphorylation on TRAIL-induced apoptosis. Here we report that salubrinal or GADD34 knockdown enhances TRAIL-induced hepatoma cell apoptosis in caspase-dependent manner. Treatment with salubrinal leads to an increase in TRAIL-induced eIF2a phosphorylation, CHOP and Bim expression. CHOP or Bim knockdown blunts the stimulation of TRAIL-induced apoptosis by salubrinal.
Results
Salubrinal enhance TRAIL-induced eIF2a phosphorylation and CHOP expression. Previous study indicated that salubrinal induced eIF2a phosphorylation and its downstream CHOP expression without affecting the transcription-dependent branch of the UPR. 20 CHOP is one of the components of the ER stress-mediated apoptosis pathway. 26 To determine the effects of salubrinal on eIF2a phosphorylation and other UPR elements in hepatoma cells, HepG2 cells (Figures 1d and e) . These results demonstrated that salubrinal enhanced TRAIL-induced eIF2a phosphorylation and CHOP expression.
CHOP reportedly upregulates DR5 expression. 27 To detect whether salubrinal affected DR5 expression, HepG2 cells were treated with salubrinal, TRAIL or both for 24 h. Western blotting analysis revealed that the combined treatment with salubrinal and TRAIL did not induce any significant changes in the protein levels of DR5 (Figure 1f ). These data indicated that salubrinal did not enhance TRAIL-induced apoptosis through upregulating DR5.
Salubrinal potentiates the inhibition of hepatoma cells survival by TRAIL. Previous studies demonstrated that salubrinal inhibited ER stress-induced apoptosis in neural cells but enhanced proteasome inhibitior-induced apoptosis in leukemia cells and multiple myeloma cells. [20] [21] [22] [23] To determine whether combination of salubrinal and TRAIL could synergistically inhibit hepatoma cells survival, HepG2 and BEL-7402 cells were treated with or without salubrinal, TRAIL or both, followed by observing colonies formation 2 weeks after the treatment. Clonogenic assays on HepG2 and BEL-7402 cells demonstrated that salubrinal significantly enhanced the inhibitory effect of TRAIL on cell survival ( Figure 2 ). Whereas treatment with salubrinal alone did not affect colony formation, there were much less colonies formed in cells treated with both salubrinal and TRAIL than that in cells treated with TRAIL alone. Meanwhile, the survived colonies in cells treated with both salubrinal and TRAIL tended to be much smaller than that in cells treated with TRAIL alone (Supplementary Tables S1 and S2 ).
Salubrinal potentiates TRAIL-induced caspase activation and apoptosis. To detect whether salubrinal potentiated TRAIL-induced apoptosis, HepG2 and BEL-7402 cells were treated with salubrinal, increasing doses of TRAIL or both for 24 h, followed by Hoechst 33342 staining. Treatment of Caspases are major effectors of TRAIL-induced apoptosis. To investigate whether salubrinal can enhance TRAILinduced caspase activation, HepG2 cells were treated with salubrinal, TRAIL or both for 24 h, followed by western blotting analysis of the cleavage of an effector caspase, caspase-7, and its substrate PARP. Treatment with salubrinal or TRAIL alone weakly induced caspase-7 and PARP cleavage. However, combination of salubrinal and TRAIL resulted in a dramatic increase in caspase-7 and PARP cleavage ( Figure 4a ). Similar effects were detected in BEL-7402 cells (Figure 4b ).
To determine whether eIF2a mutant (S51D), a mimic of phosphorylated eIF2a (S51), has a similar effect to salubrinal, HepG2 cells were transfected with wild-type eIF2a or eIF2a mutant (S51D) plasmid, followed by treatment with or without TRAIL. Overexpression of eIF2a mutant (S51D) enhanced TRAIL-induced CHOP expression, caspase 7 and PARP cleavage and apoptosis (Figure 4c and Supplementary Figure S3 ). These data suggest that eIF2a mutant (S51D) can mimic the effect of salubrinal on TRAILinduced apoptosis.
To further determine the role of eIF2a phosphorylation in salubrinal's sensitization of hepatoma cells to TRAIL-induced apoptosis, we transfected wild-type eIF2a or eIF2a S51A allele, a phosphorylation-deficient mutant of eIF2a, into HepG2 cells, followed by treatment with or without salubrinal and TRAIL. Overexpression of phosphorylation-deficient eIF2a inhibited TRAIL-induced CHOP expression, caspase 7 and PARP cleavage and abrogated the stimulatory effect of salubrinal on TRAIL-induced CHOP expression, caspase 7 and PARP cleavage and apoptosis (Figure 4d and supplementary Figure S4 ). These data suggest that the stimulation of TRAIL-induced apoptosis by salubrinal is due, at least in part, to inhibition of eIF2a dephosphorylation.
Additionally, treatment with caspase inhibitor abrogated the effects of TRAIL and salubrinal on apoptosis in both HepG2 and BEL-7402 cells ( Figure 5 ). These data indicated that salubrinal potentiated TRAIL-induced apoptosis through caspase activation.
GADD34 knockdown sensitizes hepatoma cells to TRAIL. Earlier reports indicated that GADD34 played an important role in the UPR. 19, 28 GADD34 interacted with protein phosphatase 1 to dephosphorylate eIF2a, leading to a negative feedback loop and translational recovery, which mitigated cellular stress. 19, 28, 29 Salubrinal selectively inhib- ited the GADD34/PP1-mediated dephosphorylation of eIF2a. 20 To detect whether GADD34 knockdown potentiated TRAIL-induced eIF2a phosphorylation, CHOP expression, caspase 7 and PARP cleavage, HepG2 and BEL-7402 cells were transfected with the control or GADD34 siRNA, followed by treatment with or without TRAIL for 24 h. GADD34 knockdown did not induce eIF2a phosphorylation and CHOP expression but promoted TRAIL-induced eIF2a phosphorylation, CHOP expression,caspase-7 and PARP cleavage (Figures 6a and b) . These data indicated that GADD34 knockdown could potentiate the induction of eIF2a phosphorylation, CHOP expression and caspase-7 activation by TRAIL.
Next, we investigated the effects of GADD34 knockdown on TRAIL-induced apoptosis. Knockdown of GADD34 significantly enhanced TRAIL-induced apoptosis in both HepG2 and BEL-7402 cells. Treatment with caspase inhibitor abrogated the effects of TRAIL and GADD34 knockdown on apoptosis (Figures 6c and d) . These data suggest that GADD34 knockdown could sensitize hepatoma cells to TRAIL by promoting caspase activation.
Upregulation of CHOP contributes to the enhancement of TRAIL-induced apoptosis by salubrinal. To determine the functional significance of salubrinal-induced CHOP upregulation, we investigated whether downregulation of CHOP by small interfering RNA (siRNA) could inhibit the synergistic effects of salubrinal and TRAIL on hepatoma cells. HepG2 cells were transfected with the control or CHOP siRNA, followed by treatment with salubrinal, TRAIL or both for 24 h. CHOP knockdown led to significant decrease in apoptosis induced by combination of salubrinal and TRAIL but had little effects on cells treated with TRAIL alone (Figures 7a and b) . Knockdown of CHOP in HepG2 cells significantly inhibited caspase 7 and PARP cleavage induced by the combined treatment with salubrinal and TRAIL (Figure 7c ). CHOP knockdown in BEL-7402 cells also led to significant decrease in caspase 7 and PARP cleavage and apoptosis induced by combination of salubrinal and TRAIL (Figure 8 ). Taken together, these results suggested that salubrinal-induced CHOP expression was indispensable for enhancing TRAIL sensitivity in hepatoma cells.
Bim is a CHOP-regulated proapoptotic protein that mediates the stimulatory effect of salubrinal on TRAILinduced apoptosis. Previous study suggests that Bim is a CHOP-regulated proapoptotic protein that mediates ER stress-induced apoptosis. 30 To determine the effect of salubrinal and TRAIL on Bim expression, HepG2 and BEL-7402 cells were treated with or without salubrinal and TRAIL, (Figures 9a and b) . In addition, CHOP knockdown abrogated the upregulation of Bim by salubrinal and TRAIL (Figures 9c and d) , indicating that salubrinal and TRAIL induced Bim through CHOP.
Finally, we investigated whether Bim mediated the stimulatory effect of salubrinal on TRAIL-induced apoptosis. Western blotting analysis demonstrated that Bim knockdown blunted the stimulatory effect of salubrinal on TRAIL-induced PARP cleavage in both HepG2 and BEL-7402 cells (Figures 10a and b) . Moreover, Bim knockdown abrogated the enhancement of TRAIL-induced apoptosis by salubrinal in HepG2 and BEL-7402 cells (Figures 10c and d ). These data demonstrate that Bim mediates the stimulatory effect of salubrinal on TRAIL-induced apoptosis.
Discussion
TRAIL is one of the apoptosis-inducing proteins that have been tested in treating tumors. 31 As an extracellular signal, TRAIL can elicit oxidative stress that mediates TRAIL-induced apoptosis. 32 RNAi-based screening has revealed that some genes can either inhibit or enhance TRAIL-induced apoptosis. 33 Previous study demonstrates that TRAIL induces eIF2a phosphorylation, a modifier of global protein synthesis. However, it is unclear how eIF2a phosphorylation would affect TRAIL-induced apoptosis. In this study, we show that inhibition of eIF2a dephosphorylation enhances TRAILinduced apoptosis. Salubrinal, an inhibitor of GADD34-PP1c complex that is responsible for eIF2a dephosphorylation, enhances TRAIL-induced eif2a phosphorylation and apoptosis. Similar effects are observed in GADD34-knockdown cells.
It remains unclear how TRAIL induces eIF2a phosphorylation. Although TRAIL may induce reactive oxygen species (ROS) accumulation and ROS is one of the inducers of eIF2a phosphorylation, 34 treatment with antioxidant does not prevent TRAIL-induced eIF2a phosphorylation (data not shown). eIF2a phosphorylation is also a component of integrated response to ER stress that usually induces GRP78, an ERresident chaperone that has critical roles in physiological and pathological stress. 35 However, TRAIL induces eIF2a phosphorylation without upregulating GRP78 expression. Thus, it is less likely that TRAIL induces eIF2a phosphorylation as a result of ER stress. Phosphorylation of eIF2a represents a kind of cellular stress response leading to reduced protein synthesis. Reduced translation would create a time window to repair cell damage or recover from stress. From this point of view, phosphorylation of eIF2a is cytoprotective. However, prolonged shutdown of protein synthesis would also be deleterious, because it may break cellular homeostasis. Therefore, eIF2a phosphorylation usually couples with induction of GADD34 expression, which in turn recruits PP1c to dephosphorylate eIF2a and restores protein synthesis. In this study, TRAIL upregulated GADD34 expression in BEL-7402 cells but not in HepG2 cells, possibly owing to the relatively high basic levels of GADD34 and to the relatively low induction of eIF2a phosphorylation by TRAIL in HepG2 cells.
Although salubrinal protects cells from ER stress-induced apoptosis in neural cells, it sensitizes leukemia cells to ER stressor and proteasome inhibition. 22 Also, the pro-apoptotic function of eIF2a phosphorylation in response to TRAIL and proteasome inhibition contrasts with the anti-apoptotic activities of eIF2a kinases described for other stress conditions. For example, treatment of PEK À / À MEF cells with the ER stress inducer thapsigargin led to increased apoptosis compared with its wild-type counterpart. 36 Loss of GCN2 leads to elevated apoptosis in MEF cells following exposure to UV irradiation. 37 GCN2 phosphorylation of eIF2a in response to UV irradiation facilitates activation of NF-kB but does not lead to detectable accumulation of the pro-apoptotic factor CHOP. These studies suggest that the effects of salubrinal on stress-induced apoptosis may be cell type-specific or contextdependent. The primary eIF2a kinase activated by proteasome inhibition is GCN2, while the primary eIF2a kinase activated by TRAIL is PKR. 21, 38 Loss of eIF2a phosphorylation contributes to reduced levels of caspase activation and diminished apoptosis in response to MG132 treatment, while inhibition of eIF2a dephosphorylation by salubrinal leads to increased caspase activation and apoptosis in response to Figure 6 GADD34 knockdown sensitizes hepatoma cells to TRAIL. (a) HepG2 cells were transfected with negative control siRNA (siCtrl) or siRNA to GADD34 (siGADD34). Forty-eight hours later, the cells were treated with 100 ng/ml TRAIL for further 24 h. Total proteins were harvested and subjected to western blotting analysis of P-eIF2a, CHOP, cleaved caspase-7, PARP, GADD34 and b-actin. (b) BEL-7402 cells were transfected with negative control siRNA (siCtrl) or siRNA to GADD34 (siGADD34). Forty-eight hours later, the cells were treated with 25 ng/ml TRAIL for further 24 h. Total proteins were harvested and subjected to western blotting analysis of P-eIF2a, CHOP, cleaved caspasse-7, PARP, GADD34 and b-actin. (c) HepG2 cells were transfected with negative control siRNA (siCtrl) or siRNA to GADD34 (siGADD34). Forty-eight hours after transfection, the cells were treated with or without 100 ng/ml TRAIL and 20 mM z-VAD-fmk for 24 h. Apoptosis was assessed by Hoechst 33342 staining. The apoptosis rate is plotted. Columns, mean percentage of strongly Hoechst-positive cells; bars: S.D. (d) BEL-7402 cells were transfected with negative control siRNA (siCtrl) or siRNA to GADD34 (siGADD34). Forty-eight hours after transfection, the cells were treated with or without 25 ng/ml TRAIL and 20 mM z-VAD-fmk for 24 h. Apoptosis was assessed by Hoechst 33342 staining. The apoptosis rate is plotted. Columns, mean percentage of strongly Hoechst-positive cells; bars, S.D. eIF2a phosphorylation and TRAIL-induced apoptosis Y Teng et al proteasome inhibition. 22 Similar to proteasome inhibitors, inhibition of eIF2a dephosphorylation leads to increased apoptosis in response to TRAIL via caspase-dependent mechanism. Another study by Moon et al. 39 also demonstrated that salubrinal could potentiate apoptosis induced by a combination of guggulsterone and TRAIL via DR5 upregulation, while the effect of salubrinal on apoptosis induced by TRAIL alone was not reported.
Induction of CHOP function is one important reason for the pro-apoptotic function of eIF2a kinases or salubrinal during proteasome inhibition. Inhibition of eIF2a dephosphorylation also enhances TRAIL-induced CHOP expression. Although knockdown of CHOP does not prevent TRAILinduced apoptosis, it abrogates the potentiation of TRAILinduced apoptosis by salubrinal. These data suggest that CHOP is responsible for the stimulation of TRAIL-induced apoptosis by salubrinal. The mechanism underlying CHOPinduced apoptosis is complex. CHOP may induce cell death by promoting protein synthesis and oxidation in the stressed ER. 40 In addition, studies examining the mechanism of CHOP-induced apoptosis identified numerous target genes, including Bcl2, GADD34, ER oxidoreductin 1 (ERO1a), tribbles-related protein 3 (TRB3) and Bim. 30, 41 Although CHOP mainly upregulates gene expression, Bcl2 is otherwise 42 Also, CHOP reportedly enhances DR5 expression. 27 However, neither salubrinal nor combination of salubrinal and TRAIL affects DR5 expression. Thus, salubrinal does not potentiate TRAIL-induced apoptosis by upregulating DR5 expression.
This study demonstrates that maintaining eIF2a phosphorylation through drugs like salubrinal can potentiate killing of hepatoma cells by TRAIL. We therefore propose that salubrinal or similar compounds affecting phosphorylation of eIF2a may serve as a potential strategy to maximize TRAIL efficiency and decrease tumor cell resistance to this agent. Except for bortezomib and TRAIL, it would be interesting to test whether salubrinal can enhance the therapeutic effects of other anti-cancer agents.
Materials and Methods
Reagents and antibodies. Salubrinal was purchased from Enzo Life Sciences Inc. (San Diego, CA, USA) and dissolved in DMSO to 10 mM and stored at À 20 1C. Recombinant Human TRAIL/Apo2L was purchased from PeproTech Inc. (Rocky Hill, NJ, USA) and prepared by reconstituting in deionized water and by diluting in Dulbecco's Minimal Essential Medium (DMEM) to 50 mg/ml and stored at À 20 1C. The caspase inhibitor z-VAD-fmk was purchased from Beyotime Institute of Biotechnology (Nantong, Jiangsu, China). Anti-GRP78, anti-DR5, anti-phosphorylated eIF2a, anti-CHOP, anti-caspase-7 and anti-PARP antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-GADD34 antibody was purchased from GeneTex Inc. (Irvine, CA, USA). Anti-Bim antibody was purchased from Epitomics Inc. (Burlingame, CA,USA). Anti-b-actin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Plasmid and cloning. The EGFP-tagged expression plasmids for eIF2a and its mutants (pEGFP-N1-eIF2a; pEGFP-N1-eIF2a-S51D; pEGFP-N1-eIF2a-S51A) were generated by PCR subcloning of the corresponding eIF2a cDNA in expression plasmids kindly provided by Dr. Roland M. Schmid (Department of Medicine 2, Technical University of Munich, Munich, Germany) into pEGFP-N1. Integrity of subcloned sequences was verified by automated DNA sequencing (GENEWIZ, Suzhou, China).
Cell culture. Hepatoma cell lines HepG2 and BEL-7402 were obtained from Cell Lines Bank, Chinese Academy of Science (Shanghai, China). The cells were maintained in DMEM containing 10% fetal bovine serum, 100 U/ml of penicillin and 100 mg/ml streptomycin sulfate and incubated at 37 1C in a humidified atmosphere of 5% CO 2 .
Transient transfection. For transfection, 40 000 cells were plated into six-well plates and incubated for 1 day. LipofecTAMINE 2000 reagent (Invitrogen, Carlsbad, CA, USA) was diluted in 250 ml of Opti-MEM I reduced serum medium and incubated at room temperature for 5 min. In addition, pEGFP-N1-eIF2a (S51D) was diluted in 250 ml of Opti-MEM I reduced serum medium and mixed with the prediluted LipofecTAMINE 2000. The mixture was incubated at room temperature for 20 min. 4 mg Plasmid was added into each well and incubated at 371 C. Cells were transfected at a density of 70-80% and used for experiments 24 h after transfection.
RNA interference. The target sequences used for knockdown of CHOP, GADD34 and Bim were 5'-GCCUGGUAUGAGGACCUGC-3 0 , 5 0 -GGACACUGCAA GGUUCUGA-3 0 , 5 0 -CAACCACUAUCUCAGUGCA-3 0 , respectively. The negative control siRNA was purchased from Ribobio Co., Ltd. (Guangzhou, China). The double-stranded siRNA duplex was dissolved in DEPC-treated water. For transfection, 40000 cells were plated into 6-well plates and incubated for one day. LipofecTAMINE 2000 reagent (Invitrogen) was diluted in 250 ml of Opti-MEM I reduced serum medium and incubated at room temperature for 5 min. In addition, siRNA duplex was diluted in 250 ml of Opti-MEM I reduced serum medium and mixed with the pre-diluted LipofecTAMINE 2000. The mixture was incubated at room temperature for 20 min. Inall, 50 nM of siRNA was added into each well and incubated at 37 1C.
Western blotting. Cells were washed twice with phosphate-buffered saline and harvested with cold RIPA lysis buffer containing protease inhibitors. Cell lysates were collected from culture plates using a rubber policeman, and protein was collected by centrifugation. Protein concentrations were determined by bicinchoninic acid protein assay (Pierce Biotechnology, Rockford, IL, USA). Thirty micrograms of proteins were boiled in 4 Â loading buffer for 10 min, then loaded into 10% Tris-HCl-Polyacrylamide gels and transferred to PVDF membrane (Millipore Corporation, Billerica, MA, USA). Membranes were incubated with primary antibodies and appropriate HRP-secondary antibodies. Detection was performed with chemiluminescent agents.
Clonogenic assay. To determine the effect of salubrinal and TRAIL on the clonogenicity, hepatoma cells were plated in six-well plates at 2000 cells per well. After 24 h, the cells were treated with or without salubrinal and TRAIL for 48 h. After being rinsed with fresh medium, cells were allowed to grow in the absence of drugs for 14 days to form colonies. The cells were fixed and stained with Giemsa dye liquor to visualize cell colonies. For TUNEL assay, replicate cultures of hepatoma cells were plated in tissue culture plates. The next day, the cells were treated with or without salubrinal and TRAIL for 24 h. Then the cells were fixed in 4% paraformaldehyde for 60 min. Next, the cells were permeabilized using 0.25% Triton X-100 in PBS for 2 min, followed by incubating with TUNEL solution and DAPI solution at 37 1C for 60 min without light. The apoptotic cells were examined under a fluorescence microscope. Green fluorescence can be observed in the nuclei of apoptotic cells. All cells show blue fluorescence with DAPI. Quantification of all the cells and apoptotic cells in the same fields was performed by taking the images in random fields and counting at least 200 cells in four random fields in each well.
Statistical analysis. One-way ANOVA with least significant difference post hoc test was used to test for the differences in cell viability and apoptosis rate.
All statistical tests were two-tailed, and difference was considered statistically significant when Po0.05. 
